Oncology Analytics Raises $28 Million Series C Financing Led by Baird Capital
National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund
FDA Oncology Drug Approvals
Q2 - 2020
Data Driven Utilization Management, Purpose Built for Oncology
Oncology Analytics® provides health plans, providers, and patients with a data-driven, utilization management solution that delivers real-world, evidence-based analytics focused exclusively for oncology
Oncology Analytics named to CB Insights’ Digital Health 150
The most promising 150 private digital health startups working to transform the healthcare industry with new models of primary care to emerging tech solutions for providers
Bringing together science, technology and analytics to support evidence-based decision-making in oncology utilization management addresses the two biggest challenges associated with making informed and timely patient treatment decisions: speed and evidence. This type of approach requires deep analytics and insights into a health plan’s cancer drug spend to ensure that anti-cancer therapies are based on science and evidence-based protocols specific to the patient’s unique circumstances and needs.
Oncology Analytics offers critical technology and services that address the primary challenges and gaps health plans face in advancing a data-driven strategy for oncology utilization management:
Harvard Pilgrim Implements Real-World Data-Driven Prior Authorization Solution That Leverages Both Clinical and Claims Data
New Offering Designed to Help Health Plans Navigate the Anti-Cancer Drug Market to Improve Member Treatment Recommendations
Articles & Press
As coronavirus disease 2019 (COVID-19) has transformed the world we live in, so too has it changed the paradigms of treatment for many cancers.
The following article is the fifth in a five-part series on The Top Five Ways for Health Plans to Manage Oncology Drug Costs While Improving Member Treatment Options.